DNA

Interim Results for the Six Months Ended 30 June 2024

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued…

1 year ago

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global…

1 year ago

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,…

1 year ago

Angle PLC Announces Exclusive agreement for DNA NGS panel

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with…

1 year ago

Metagenomi to Present at Chardan’s 8th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing…

1 year ago

NewVue Announces Strategic Partner Agreement with Konica Minolta Healthcare to Enhance Radiology Workflow

Exa Enterprise Imaging At RSNA 2023, Konica Minolta Healthcare introduces Exa Connect and Exa Clear Authorization as part of the…

1 year ago

Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities…

1 year ago

Zymo Research Stands by Its Innovative cfDNA Technology in Response to Qiagen’s Lawsuit

IRVINE, Calif., Sept. 18, 2024 /PRNewswire/ -- Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent…

1 year ago

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and…

1 year ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene…

1 year ago